Category: Fellows Posters
Purpose: Per recommendation by the Infectious Disease Society of America (ISDA) and American Thoracic Society (ATS), the duration of antibiotic use for community acquired pneumonia (CAP) should typically be about 5-7 days. However, there seems to be excessive duration of antibiotic therapy for treatment of CAP in the hospital setting. This medication use evaluation is aimed to evaluate inappropriate duration of antibiotic therapy as well as identify possible adverse events, costs, and outcomes that are associated with it.
This project will be submitted to the Institutional Review Board for approval. Patients who were discharged between January 2018 and December 2018 from two community hospitals with an associated diagnosis of community acquired pneumonia will be identified using the electronic medical record system. Only patients who are over the age of 18 and received antibiotic therapy for at least 4 days will be included. Patients who will be excluded are those who: did not receive antibiotic therapy within the 1st or 2nd day of hospitalization, received antibiotics for additional or unrelated infectious indications, were pregnant, were severely immunocompromised, or who passed away during their hospital stay.
The following data will be pulled: patient age, sex, weight, height, CrCl, procalcitonin levels, imaging, cultures, associated diagnoses, temperature, allergies, antibiotics prescribed (including information on indication, interventions filed by the pharmacist for treatment, duration, and end date), adverse events, and duration of hospital stay. All data will be recorded without patient identifiers and maintained confidentially. The reviewer will then review the antibiotic use and duration of therapy for the identified patients to assess if the typical practice follows the ISDA and ATS guidelines. The reviewer will also assess the rate of adverse events and readmissions.